The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
about
Clinical use of whole genome sequencing for Mycobacterium tuberculosisRepurposing clinically approved cephalosporins for tuberculosis therapyDiagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance MutationsMycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisDefining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China.Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa.Rifabutin: where do we stand in 2016?Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.Population screening and treatment of Helicobacter pylori infection.Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks.What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates.Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray.Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.
P2860
Q26752636-2C5001C7-407D-4BC5-B1EF-E9E8BEE7F51CQ28828720-D0B2D9C1-1EAE-4687-B739-76876CD99B43Q28831411-EF1304C0-84EB-4C96-A68E-617CB0BD235AQ30385967-30D3B8AD-4AF5-4022-8143-5FECCA2FC807Q33667215-4C225BA2-B111-47A3-BE6C-C4CA860A8499Q33926262-7CA9A82E-5791-4ECF-ADFB-D1FBD0303CF7Q35554602-DFD14EF1-FFC0-4078-936A-F0E75BE2AAE5Q36247548-B4AD9269-E86D-403A-AE55-3FF6F6A0CEC2Q36917933-1A93C225-13D8-4358-884B-A76CA2AC476CQ37471180-D85017CD-72A6-4F70-9C70-40D2158C3FFEQ38786540-2C92BE5D-3A7B-46E2-8D43-0A08A2AC1CF6Q38929849-EF43B89C-BED5-4649-B6BA-6E3DB7B5B340Q39067619-6983C402-AEB5-42F7-8BB9-7076057CC15EQ40209976-98EF2567-166E-4D6E-AC02-7FAB627E909EQ42373066-B8A3D95A-2990-4367-9EE0-A8E2E98B26C4Q46319545-564E4414-BFD2-4D8E-AD0C-23C67B69CF97Q47135600-CD16D343-07B5-4B28-AB66-211DF1AEC974Q53221993-D860B979-A359-41A3-AB0D-148AA72EB52FQ53687059-3A09A735-2841-468F-A2BA-199FECED041C
P2860
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@ast
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@en
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@nl
type
label
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@ast
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@en
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@nl
prefLabel
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@ast
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@en
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@nl
P2093
P2860
P3181
P1433
P1476
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks
@en
P2093
Erik C Böttger
Frederick A Sirgel
Paul D van Helden
Thomas C Victor
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0059414
P407
P577
2013-01-01T00:00:00Z